Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Takeda's Dengue Vaccine Candidate Aims To Avoid Dengvaxia Problems

Executive Summary

TAK-003 is designed to be effective in those never exposed to dengue; Takeda expects Phase III results by end of 2018.

Advertisement

Related Content

Takeda To Press On With Core R&D Strategy Post-Shire
Takeda/Shire Merger: Five Things To Worry About
Brakes On Sanofi’s Dengvaxia Prospects Amid WHO-SAGE Screening Advice?
Sanofi's Dengue Vaccine Gets WHO Backing In People Previously Infected

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

PS122160

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel